key: cord-0736829-oabt7r7e
authors: Wu, Yuanyuan; Wang, Ting; Guo, Chunying; Zhang, Dongmei; Ge, Xiaojing; Huang, Zhaoxing; Zhou, Xianshan; Li, Yinping; Peng, Qingzhen; Li, Jinan
title: Plasminogen improves lung lesions and hypoxemia in patients with COVID-19
date: 2020-04-10
journal: QJM
DOI: 10.1093/qjmed/hcaa121
sha: fbc08fad1bfcfadb9a7e0a11957f822362b6f94c
doc_id: 736829
cord_uid: oabt7r7e

BACKGROUND: Lungs from patients with coronavirus disease 2019 (COVID-19) have shown typical signs of acute respiratory distress syndrome (ARDS), formation of hyaline membrane mainly composed of fibrin, and ‘ground-glass’ opacity. Previously, we showed plasminogen itself is a key regulator in fibrin degradation, wound healing and infection. AIM: We aimed to investigate whether plasminogen can improve lung lesions and hypoxemia of COVID-19. DESIGN: Thirteen clinically moderate, severe or critical COVID-19 patients were treated with atomization inhalation of freeze-dried plasminogen. METHODS: Levels of their lung lesions, oxygen saturation and heart rates were compared before and after treatment by CT scanning images and patient monitor. RESULTS: After plasminogen inhalation, conditions of lung lesions in 5 clinically moderate patients have quickly improved, shown as the decreased range and density of ‘ground glass’ opacity. Improvements of oxygen saturation were observed in 6 clinically severe patients. In the 2 patients with critical conditions, the oxygen levels have significantly increased from 79-82% to 91% just about 1 hour after the first inhalation. In 8 of 13 patients the heart rates had slowed down. For the 5 clinically moderate patients, the difference is even statistically significant. Furthermore, a general relief of chest tightness was observed. CONCLUSION: Whereas it is reported that plasminogen is dramatically increased in adults with ARDS, this study suggests that additional plasminogen may be effective and efficient in treating lung lesions and hypoxemia during COVID-19 infections. Although further studies are needed, this study highlights a possible hope of efficiently combating this rapid epidemic emergency.

Since December 2019, a sudden outbreak of infectious pneumonia caused by novel coronavirus, SARS-CoV-2, occurred in Wuhan, Hubei Province, China and is quickly spreading national wide and also to other parts of the world. 1 As of March 4, 2020, the virus has been found in 59 countries with 80,710 confirmed cases in China, including 3,045 fatalities. 2 Due to rapid transmission dynamics and multiple transmission ways, COVID-19 has caused panic in the world.

The clinical features of COVID-19 are very similar to that of severe acute respiratory syndromelike coronavirus (SARS) outbreak in 2003. 3, 4 In the early phases of the disease, acute respiratory infection symptoms occur. Although in most cases the disease is acute and can be resolved by itself, in severe or critical cases, patients may suffer and even die from acute respiratory distress syndrome (ARDS), acute respiratory failure, and other serious complications, mainly due to massive diffuse alveolar damage and early hyaline membrane formation. 4, 5 As a predominant and early pathological feature, formed hyaline membranes consist of fibrin matrix incorporating the whole spectrum of serum proteins and cellular debris, 6-8 which forms a barrier to inhibit gas exchange and pulmonary surfactant resulting in ARDS. Moreover, in hyaline membrane disease of premature infants, fibrin deposition in alveoli and alveolar ducts is a crucial factor that may result in death. 9, 10 The plasminogen activator (PA) system is a broad-spectrum protease system where the active component, plasmin, is formed from its precursor, plasminogen and is important in degrading main components of the extracellular matrix including fibrin. Plasminogen is classically regarded as inert and excessive, and the regulation of the PA system is by the activators and inhibitors of the system. 11 However, we have shown before that plasminogen itself is a key regulator in many pathological processes including fibrinolysis, wound healing and infection. [12] [13] [14] [15] Previous studies have demonstrated different results on whether plasminogen is sufficient in ARDS.

Premature infants with hyaline membrane disease and ARDS have been reported to have low levels of circulating plasminogen and PAs, 9,16-18 but increased levels of the PA inhibitor. 16 Thus, intravenous supplementation of plasminogen was effective in lowering the occurrence of premature infant ARDS and death. 9, 17, 18 However, other studies later on showed that in the bronchoalveolar lavage of the normal adult patients with ARDS, dramatically increased and sufficient amounts of plasminogen, reduced levels of urokinase-type PA and markedly enhanced levels of PA inhibitor-1 and α2-antiplasmin were found. [19] [20] Hence, although hyaline membrane disease in premature infants and COVID-19 pneumonia mainly in normal adults have completely distinct etiologies, inspired by our previous studies, we hypothesize that additional plasminogen supplementation to these COVID-19 patients may still benefit them. As the first attempt, in the current study, we investigated the therapeutic effects of plasminogen by atomization inhalation on COVID-19. The results suggest that using plasminogen by atomization inhalation is an effective and efficient way to combat this rapid epidemic emergency.

The 13 study subjects were 30-78 years old females and males diagnosed as COVID-19 with clinically moderate, severe or critical clinical severities, in accordance with the National Health Commission guidelines. 21 

Sterile, freeze-dried plasminogen of 5mg per vial from human plasma fraction III was produced at facilities with GMP compliance and provided by Talengen Institute of Life Sciences. The safety of the virus inactivation process was confirmed by an independent third party testing organization. Atomization inhalation of 10mg plasminogen dissolved in 2ml sterile water was given twice daily for severe and critical COVID-19 subjects, and once daily for moderate COVID-19 subjects. Treatment profile is shown in Table 1 .

High-resolution CT scan (NeuViz 16 Classic, Neusoft, China) of the chest was taken at Suixian

Hongshan Hospital a few days before the first and after the last administration of plasminogen for the 5 moderate COVID-19 subjects.

Real-time oxygen saturation and heart rates were monitored by patient monitor (iPM5, Mindary, China) and the values were documented at 1 hour before and few hours after atomization inhalation of https://mc.manuscriptcentral.com/qjm plasminogen.

Statistical analysis was performed on SPSS 16.0 (IBM Corporation). Heart rate of the same severity group before and after administration of plasminogen were analyzed with two-tailed t-test, and *, p < 0.05 was considered statistically significant.

To study the effects of plasminogen on lung lesions, high-resolution CT scanning of chest was performed on COVID-19 patients. Before administration of plasminogen, the chest CT images of 5 moderate COVID-19 patients showed multiple patchy/punctate 'ground-glass' opacities in bilateral lungs with unclear margins and heterogeneous density, and also scattered punctate density in mediastinum ( Fig. 1 and Table 2 ). Despite the 5 patients received the daily common supportive treatments with antibiotics and traditional Chinese medicine, the density and range of 'ground glass' opacities in lung increased over time, suggesting a rapid deleterious progress of the disease (CT scanning examination record, not shown here). Surprisingly, just after 2-3 times of plasminogen inhalation, the CT results showed that the numbers, the range and the density of lung lesion-focal in all of the 5 patients treated have diminished or even partially disappeared. Patchy or punctate 'ground glass' opacities have significantly decreased or absorbed. This indicated that atomization inhalation of plasminogen rapidly improves lung lesions caused by COVID-19 infection.

We further investigated the effects of plasminogen on oxygen saturation. Throughout the entire plasminogen administration period, the oxygen saturation levels were detected by patient monitors on clinically severe or critical COVID-19 patients with oxygen supplementation by a nasal cannula that delivered oxygen at constant concentrations of at least 80% or 100%, respectively. As shown in Table 3 , although generally having good oxygen saturation levels, the oxygen saturation values of 5 out of 6 severe COVID-19 patients still increased 1-4% after plasminogen administration. Only in one patients, perhaps due to administration of plasminogen for just once, the oxygen saturation value decreased from 91% to 89%. In these 2 patients with critical conditions, the oxygen levels have significantly increased from 79-82% to 91% just about 1 hour after the first inhalation and stabilized at around 91% thereafter https://mc.manuscriptcentral.com/qjm (Detailed data not shown here). However, due to the critical conditions of these two patients, they were transferred to intensive care unit, so that the follow-up treatment of plasminogen was interrupted.

Nevertheless, these data indicate that plasminogen generally improves the oxygen saturation levels of severe and critically severe COVID-19 patients, especially in these patients that have particularly low oxygen levels.

All of the COVID-19 patients also underwent heart rate examination during the study. The results showed that whereas before inhalation of plasminogen, these patients generally showed higher heart rates.

After treatment, in 8 out of 13 COVID-19 patients the heart rates had slowed down as much as 26 beats per min, 2 increased and 3 no changes. Statistical analysis showed that despite patient samples are sparse, the average heart rates after treatment in general have decreased in all of the three groups and for the moderate group, the statistics reached significance (P<0.05) (in Table 4 and Fig 2) . These results indicate that plasminogen can generally slow down the high beating rates and alleviate the burden of hearts of COVID-19 patients.

As of March 4 2020, COVID-19 epidemic has quickly become a global healthcare emergency that affects more than 95,902 people in 59 countries. 22 In this study, by atomization inhalation of plasminogen for just a few times, lung lesions and oxygen saturation levels of COVID-19 patients have got significantly improved, suggesting plasminogen may be used as an effective and efficient way to treat the complications of the COVID-19 infection.

Examinations on postmortem biopsies from one patient died from severe infection with SARS-CoV-2 show that the major pathological characteristics of SARS-CoV-2 pneumonia are diffuse alveolar damage with cellular fibromyxoid exudates and hyaline membrane formation. 5 It is known that fibrin, the classic substrate for the PA system, is the main component of inflammatory exudation, and fibrin accumulation in the lung is a hallmark of alveolar hyaline membrane formation resulting in acute lung injury and ARDS, which may further lead to pulmonary fibrosis and death. 9 Traditionally, as an inactive pre-enzyme, it is well known and almost a doctrine that plasminogen is excessive, inert and does not have any functional roles due to plasminogen circulates in the blood at a steadily concentration about 0.2mg/ml. 23 However, we have shown that although plasminogen levels are significantly increased in the 

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

The Nature of the hyaline membrane in asphyxia of the newborn

Pulmonary Hyaline Membranes Studied with the Electron Microscope

A Histochemical Study of Pulmonary Hyaline Membrane

Plasminogen in the prevention of hyaline membrane disease

Surfactant alteration and replacement in acute respiratory distress syndrome

Cell-Associated Plasminogen Activation: Regulation and Physiological Functions

Plasminogen is a key proinflammatory regulator that accelerates the healing of acute and diabetic wounds

Beneficial and Detrimental Effects of Plasmin(ogen) during Infection and Sepsis in Mice

Protective effects of plasmin(ogen) in Staphylococcus aureus-induced arthritis

Method for preventing or treating acute thrombosis and chronic thrombosis

The fibrinolytic enzyme defect of hyaline membrane disease

Prevention of hyaline membrane disease with plasminogen: A cooperative study

Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome

Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia

Comparison with the acute respiratory distress syndrome

General Office of National Health Commission of the People's Republic of China. Office of State Administration of Traditional Chinese Medicine. Notice on the issuance of strategic guidelines for diagnosis and treatment of novel coronavirus (2019-nCoV) infected pneumonia

Real-time big data report on global new coronavirus pneumonia. 2020

Structure and function of plasminogen/plasmin system

Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China

Clear vision through the haze: a practical approach to ground-glass opacity

The lung and its Disorders in Newborn Infants

Effect of surface active lipoprotein on clotting and fibrinolysis, and of fibrinogen on surface tension of surface active lipoprotein

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Method for preventing and treating tissue and organ fibrosis. WIPO Patent Application

Method for mitigating heart disease. WIPO Patent Application

Novel method for preventing and treating cardiovascular disease. WIPO Patent Application

Method for preventing and treating pulmonary fibrosis. WIPO Patent Application

Novel method for treating diabetes. WIPO Patent Application

Method and drug for regulating blood pressure. Chinese Patent Application

We wish to acknowledge all other staff involved in the study from but not limited to the institutions of the listed authors for their assistance.

Dr. Jinan Li owns Talengen Institute of Life Sciences. The institute has applied patents on the use of plasminogen in relation to COVID-19 and is developing natural and recombinant plasminogen as a drug candidate to treat COVID-19. Other authors have declared no competing interests.

None funding support in this article.https://mc.manuscriptcentral.com/qjm